Muangman P, Muangman S, Opasanon S, Keorochana K, Chuntrasakul C, et al.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Date of publication 2009 Oct 1;volume 92(10):1300-5.
1. J Med Assoc Thai. 2009 Oct;92(10):1300-5.
Benefit of hydrocolloid SSD dressing in the outpatient management of partial
thickness burns.
Muangman P(1), Muangman S, Opasanon S, Keorochana K, Chuntrasakul C.
Author information:
(1)Burn Unit, Trauma Division, Department of Surgery, Faculty of Medicine Siriraj
Hospital, Mahidol University, Bangkok, Thailand. pmuangman@yahoo.com
Silver sulfadiazine has been used as topical medication in the treatment of
partial-thickness burns or secondary degree burns for many years. Pain during
daily wound cleansing is the main problem. Urgotul SSD, a hydrocolloid dressing
with silver sulfadiazine (SSD) has been reported to reduce infection and exhibit
antimicrobial activity in burn wounds. The purpose of the present study was to
compare the efficacy of Urgotul SSD and 1% silver sulfadiazine for treatment of
partial thickness burn wounds. The authors reviewed 68 patients who had partial
thickness burn wound less than 15% total body surface area (TBSA%) and were
treated at Siriraj outpatient burn clinic during July 2005-December 2006. All
patients were divided into two groups: Urgotul SSD treated group (34 patients)
and 1% silver sulfadiazine treated group (34 patients). The two groups were
compared by the demographic data including age, gender, % total body surface area
(TBSA) burn, % TBSA deep burn, type of burn as well as percent of wound
infection, total cost of wound dressing, pain medication, level of pain and time
of wound healing. There were no differences in demographic data of age, % TBSA
burn, % wound infection, total treatment cost of burn wound care (52 +/- 38 US$
for Urgotul SSD versus 45 +/- 34 US$ for silver sulfadiazine treated group). Time
of wound closure was significantly shorter in the Urgotul SSD treated group (10
+/- 4 days in Urgotul SSD versus 12 +/- 6 in 1% silver sulfadiazine treated
group) between both groups (p < 0.05). Average pain scores and pain medication in
Urgotul SSD treated group was significantly lower than 1% silver sulfadiazine
treated group (3 +/- 1 versus 6 +/- 2 and respectively, p < 0.05). All of the
patients who developed wound infection responded well to targeted topical and
oral antibiotic treatment. The authors conclude that Urgotul SSD has advantages
of reducing pain symptom, pain medication requirement, increased patient
convenience due to decreased time of follow-up at outpatient burn clinic,
limiting the frequency of replacement of the dressing at comparable total cost
and incidence of burn wound infection. The present study confirms the efficacy of
Urgotul SSD in the treatment of partial thickness or secondary degree burn wound
at the outpatient clinic.
PMID: 19845237 [Indexed for MEDLINE]
